Provectus Biopharmaceuticals (PVCT) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 11, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	800 S. Gay Street
Entity Address, Address Line Two	Suite 1610
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37929
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		420,279,879
Entity Information, Former Legal or Registered Name	Not Applicable
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 187,457	$ 76,576
Restricted cash	426,732	950,223
Short-term receivables		476
Prepaid expenses and other current assets	145,814	337,522
Total Current Assets	760,003	1,364,797
Equipment and furnishings, less accumulated depreciation of $117,685 and $110,994, respectively	5,329	12,020
Operating lease right-of-use asset	36,701	72,026
Total Assets	802,033	1,448,843
Current Liabilities:
Accounts payable	1,381,027	1,675,891
Unearned grant revenue	350,440	953,248
Other accrued expenses	1,558,339	3,240,436
Notes payable	110,544	277,815
Operating lease liability, current portion	37,714	48,077
Total Current Liabilities	6,224,763	9,016,895
Operating lease liability, non-current portion		25,299
Total Liabilities	6,224,763	9,042,194
Commitments, contingencies, and litigations (Note 12)
Stockholders’ Deficit:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 420,279,879 and 419,447,119 shares issued and outstanding at September 30, 2024 and December 31, 2023	420,280	419,522
Additional paid-in capital	249,258,870	244,714,967
Accumulated other comprehensive loss	(60,199)	(60,165)
Accumulated deficit	(255,055,650)	(252,690,409)
Total Stockholders’ Deficit	(5,422,730)	(7,593,351)
Total Liabilities and Stockholders’ Deficit	802,033	1,448,843
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	957	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	13,012	10,361
Nonrelated Party [Member]
Current Liabilities:
Accrued interest	19,558	22,600
Convertible notes payable	453,000	800,000
Related Party [Member]
Current Liabilities:
Accrued interest	114,141	123,828
Convertible notes payable	$ 2,200,000	$ 1,875,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accumulated depreciation, equipment and furnishings	$ 117,685	$ 110,994
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	420,279,879	419,447,119
Common stock, shares outstanding	420,279,879	419,447,119
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	957,100	12,374,000
Preferred stock, shares issued	956,985	12,373,247
Preferred stock, shares outstanding	956,985	12,373,247
Preferred stock, liquidation preference value	$ 1,095,556	$ 14,164,889
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized	23,042,900	11,241,000
Preferred stock, shares issued	13,011,823	10,361,097
Preferred stock, shares outstanding	13,011,823	10,361,097
Preferred stock, liquidation preference value	$ 148,959,354	$ 118,613,136

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Grant Revenue	$ 109,745	$ 69,733	$ 602,808	$ 436,600
Operating Expenses:
Research and development	413,987	350,792	1,442,449	1,333,399
General and administrative	651,486	433,089	1,358,206	1,399,765
Total Operating Expenses	1,065,473	783,881	2,800,655	2,733,164
Total Operating Loss	(955,728)	(714,148)	(2,197,847)	(2,296,564)
Other Income/(Expense):
Research and development tax credit	56	(167)	9,357	15,798
Interest expense, net	(58,679)	(61,524)	(176,751)	(157,589)
Total Other Expense, Net	(58,623)	(61,691)	(167,394)	(141,791)
Net Loss	$ (1,014,351)	$ (775,839)	$ (2,365,241)	$ (2,438,355)
Loss Per Common Share - basic	$ 0	$ 0	$ (0.01)	$ (0.01)
Loss Per Common Share - diluted	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted Average Number of Common Shares Outstanding - basic	419,906,732	419,515,869	419,651,259	419,503,438
Weighted Average Number of Common Shares Outstanding - diluted	419,906,732	419,515,869	419,651,259	419,503,438

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net Loss	$ (1,014,351)	$ (775,839)	$ (2,365,241)	$ (2,438,355)
Other Comprehensive Income/(Loss):
Foreign currency translation adjustments	255	(441)	(34)	(528)
Total Comprehensive Loss	$ (1,014,096)	$ (776,280)	$ (2,365,275)	$ (2,438,883)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series D-1 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 12,373	$ 9,747	$ 419,497	$ 242,954,193	$ (35,679)	$ (249,588,641)	$ (6,228,510)
Balance, shares at Dec. 31, 2022	12,373,247	9,746,626	419,497,119
Conversion of Note to Series D-1 Preferred Stock		$ 18		53,992			54,010
Conversion of Note to Series D-1 Preferred Stock, shares		18,872
Net loss						(827,454)	(827,454)
Other comprehensive loss					191		191
Balance at Mar. 31, 2023	$ 12,373	$ 9,765	$ 419,497	243,008,185	(35,488)	(250,416,095)	(7,001,763)
Balance, shares at Mar. 31, 2023	12,373,247	9,765,498	419,497,119
Balance at Dec. 31, 2022	$ 12,373	$ 9,747	$ 419,497	242,954,193	(35,679)	(249,588,641)	(6,228,510)
Balance, shares at Dec. 31, 2022	12,373,247	9,746,626	419,497,119
Net loss							(2,438,355)
Balance at Sep. 30, 2023	$ 12,373	$ 10,146	$ 419,522	244,101,958	(36,207)	(252,026,996)	(7,519,204)
Balance, shares at Sep. 30, 2023	12,373,247	10,146,818	419,522,119
Balance at Mar. 31, 2023	$ 12,373	$ 9,765	$ 419,497	243,008,185	(35,488)	(250,416,095)	(7,001,763)
Balance, shares at Mar. 31, 2023	12,373,247	9,765,498	419,497,119
Conversion of Note to Series D-1 Preferred Stock		$ 189		540,033			540,222
Conversion of Note to Series D-1 Preferred Stock, shares		188,757
Net loss						(835,062)	(835,062)
Other comprehensive loss					(278)		(278)
Balance at Jun. 30, 2023	$ 12,373	$ 9,954	$ 419,497	243,548,218	(35,766)	(251,251,157)	(7,296,881)
Balance, shares at Jun. 30, 2023	12,373,247	9,954,255	419,497,119
Conversion of Note to Series D-1 Preferred Stock		$ 122		351,110			351,232
Conversion of Note to Series D-1 Preferred Stock, shares		122,725
Net loss						(775,839)	(775,839)
Other comprehensive loss					(441)		(441)
Common stock issued for services			$ 25	2,825			2,850
Common stock issued for services, shares			25,000
Conversion of 2022 Note to Series D-1 Preferred Stock		$ 70		199,805			199,875
Conversion of 2022 Note to Series D-1 Preferred Stock, shares		69,838
Balance at Sep. 30, 2023	$ 12,373	$ 10,146	$ 419,522	244,101,958	(36,207)	(252,026,996)	(7,519,204)
Balance, shares at Sep. 30, 2023	12,373,247	10,146,818	419,522,119
Balance at Dec. 31, 2023	$ 12,373	$ 10,361	$ 419,522	244,714,967	(60,165)	(252,690,409)	(7,593,351)
Balance, shares at Dec. 31, 2023	12,373,247	10,361,097	419,522,119
Conversion of Note to Series D-1 Preferred Stock		$ 226		647,935			648,161
Conversion of Note to Series D-1 Preferred Stock, shares		226,474
Net loss						(504,042)	(504,042)
Other comprehensive loss					(415)		(415)
Balance at Mar. 31, 2024	$ 12,373	$ 10,587	$ 419,522	245,362,902	(60,580)	(253,194,451)	(7,449,647)
Balance, shares at Mar. 31, 2024	12,373,247	10,587,571	419,522,119
Balance at Dec. 31, 2023	$ 12,373	$ 10,361	$ 419,522	244,714,967	(60,165)	(252,690,409)	(7,593,351)
Balance, shares at Dec. 31, 2023	12,373,247	10,361,097	419,522,119
Net loss							(2,365,241)
Balance at Sep. 30, 2024	$ 957	$ 13,012	$ 420,280	249,258,870	(60,199)	(255,055,650)	(5,422,730)
Balance, shares at Sep. 30, 2024	956,985	13,011,823	420,279,879
Balance at Mar. 31, 2024	$ 12,373	$ 10,587	$ 419,522	245,362,902	(60,580)	(253,194,451)	(7,449,647)
Balance, shares at Mar. 31, 2024	12,373,247	10,587,571	419,522,119
Conversion of Note to Series D-1 Preferred Stock		$ 275		783,021			783,296
Conversion of Note to Series D-1 Preferred Stock, shares		273,691
Net loss						(846,848)	(846,848)
Other comprehensive loss					126		126
Forfeited shares of Series D Preferred Stock	$ (11,416)			11,416
Forfeited shares of Series D Preferred Stock, shares	(11,416,262)
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock		$ 1,141		(1,141)
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock, shares		1,141,626
Balance at Jun. 30, 2024	$ 957	$ 12,003	$ 419,522	246,156,198	(60,454)	(254,041,299)	(7,513,073)
Balance, shares at Jun. 30, 2024	956,985	12,002,888	419,522,119
Conversion of Note to Series D-1 Preferred Stock		$ 339		972,261			972,600
Conversion of Note to Series D-1 Preferred Stock, shares		339,833
Net loss						(1,014,351)	(1,014,351)
Other comprehensive loss					255		255
Conversion of accrued directors’ fees to Series D-1 Preferred Stock		$ 745		2,131,094			2,131,839
Conversion of accrued directors' fees to series D-1 preferred stock, shares		744,878
Conversion of Series D-1 Preferred Stock to Common Stock		$ (75)	$ 758	(683)
Conversion of Series D-1 preferred stock to common stock, shares		(75,776)	757,760
Balance at Sep. 30, 2024	$ 957	$ 13,012	$ 420,280	$ 249,258,870	$ (60,199)	$ (255,055,650)	$ (5,422,730)
Balance, shares at Sep. 30, 2024	956,985	13,011,823	420,279,879

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows From Operating Activities:
Net loss	$ (2,365,241)	$ (2,438,355)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		2,850
Non-cash operating lease expense	35,325	33,613
Depreciation	6,691	6,691
Changes in operating assets and liabilities
Short term receivables	465	(553)
Prepaid expenses and other current assets	267,991	359,572
Accounts payable	(294,892)	(308,728)
Unearned grant revenue	(602,808)	(436,600)
Other accrued expenses	449,721	653,664
Operating lease liability	(35,662)	(32,938)
Accrued interest	166,327	150,017
Net Cash Used In Operating Activities	(2,372,083)	(2,010,767)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	353,000	700,000
Proceeds from issuance of convertible notes payable - related parties	1,950,000	1,525,000
Repayment of short-term note payable	(243,554)	(234,997)
Repayment of 2021 convertible note payable - related party	(100,000)
Net Cash Provided By Financing Activities	1,959,446	1,990,003
Effect of exchange rates on cash and restricted cash	27	(736)
Net Decrease In Cash and Restricted Cash	(412,610)	(21,500)
Cash and Restricted Cash, Beginning of Period	1,026,799	1,431,707
Cash and Restricted Cash, End of Period	614,189	1,410,207
Cash	187,457	367,250
Restricted cash	426,732	1,042,957
Supplemental Disclosures of Cash Flow Information:
Interest
Income taxes
Non-cash investing and financing activities:
Conversion of 2021 Notes and related accrued interest to Series D-1 Preferred Stock		804,533
Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock	2,404,057	170,126
Conversion of accrued directors’ fees to Series D-1 Preferred Stock	2,131,839
Forfeited shares of Series D Preferred Stock	(11,416)
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock	1,141
Purchase of insurance policies financed by short-term note payable	$ (76,283)	$ (73,669)

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”). The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (“API”) in the drug candidates of our current clinical development programs and the formulations of our current non-clinical in vivo in vitro The Company believes that RBS targets disease in a bifunctional multi-modal manner. Direct contact by RBS with disease may lead to cell death or repair, depending on the disease being treated and the concentration of RBS being utilized in the therapeutic formulation, by one or more targeting mechanisms. Multivariate innate and adaptive immune activation, signaling, and response may follow that may manifest as stimulatory, inhibitory, or both. The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry at ClinicalTrials.gov. The Company believes that it is the first and only entity to date to make pharmaceutical-grade RBS successfully, reproducibly, and consistently at a purity of nearly 100%. The Company’s small molecule platform comprises several different drug candidates and non-clinical targets using different concentrations delivered by different routes of administration specific to each disease area and/or disease indication, including: ● Clinical development programs in oncology (intratumoral administration), dermatology (topical), and ophthalmology (topical), ● In vivo: ● In vitro: Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2023 filed with the SEC on March 28, 2024. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s cash and restricted cash were $ 614,189 426,732 5,464,760 7,652,098 2,365,241 2,438,355 2,372,083 2,010,767 The Company plans to access capital resources through possible public or private equity offerings, including additional convertible debt issuance pursuant to the 2024 Financing (see Note 5 and Note 13), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although there can be no assurance that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, there can be no assurance that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other HX-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2024 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, there can be no assurance that it will be able to obtain funds on commercially acceptable terms, or complete additional financing in a timely manner. Any such financing may result in significant dilution to stockholders. These factors raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of liabilities that may be necessary should we be unable to continue as a going concern. Our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate our continuation as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Since the date the Company’s December 31, 2023 consolidated financial statements were issued in its 2023 Annual Report on March 28, 2024, there have been no material changes to the Company’s significant accounting policies. Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets. Restricted Cash Restricted cash consists of a grant award received from the State of Tennessee. Restricted cash available as of September 30, 2024 is $ 426,732 Cash Concentrations Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 364,189 776,799 Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2024 2023 September 30, 2024 2023 Warrants - 437,500 Options 3,075,000 3,225,000 Convertible preferred stock 131,075,215 113,841,427 2021 unsecured convertible notes and accrued interest 517,451 817,766 2022 unsecured convertible notes and accrued interest 7,641,022 10,115,192 2024 unsecured convertible notes and accrued interest 1,578,423 - Total potentially dilutive shares 143,887,111 128,436,885 Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 “ Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Other Accrued Expenses

Other Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Other Accrued Expenses	4. Other Accrued Expenses The following table summarizes the other accrued expenses at September 30, 2024 and December 31, 2023: Schedule of Other Accrued Expenses September 30, December 31, 2024 2023 Accrued payroll and taxes $ 1,280,049 $ 719,460 Accrued vacation 118,264 92,985 Accrued directors’ fees - 2,330,589 Accrued other expenses 160,026 97,402 Total other accrued expenses $ 1,558,339 $ 3,240,436

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable 2024 Financing On July 11, 2024, the Board approved a Financing Term Sheet (the “2024 Term Sheet”), which set forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $ 10,000,000 Pursuant to the 2024 Term Sheet, the 2024 Notes (defined below) will automatically convert into shares of the Company’s Series D-1 Preferred Stock twelve months after the issue date of a 2024 Note, subject to certain exceptions. The 2024 Financing will be in the form of an unsecured convertible loan (the “2024 Loan”) from the investors (the “2024 Loan Investors”) and evidenced by convertible promissory notes (individually, a “2024 Note” and collectively, the “2024 Notes”). In addition to customary provisions, the 2024 Notes will contain the following provisions: (i) The 2024 Loan will bear interest at the rate of eight percent ( 8 (ii) In the event there is a change of control of the Board, the term of the 2024 Notes will be accelerated and all amounts due under the 2024 Notes may be immediately due and payable at the 2024 Loan Investors’ option; (iii) The outstanding principal amount and interest payable under the 2024 Loan may be convertible at the 2024 Loan Investors’ option into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $ 2.8620 10 (iv) The outstanding principal amount and interest payable under the 2024 Loan will be automatically convertible into shares of the Company’s Series D-1 Preferred Stock twelve (12) months after the issue date of a 2024 Note at a price per share equal to $ 2.8620 The following summarizes convertible notes payable activity during the nine months ended September 30, 2024: 2021 Financing Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ - $ 200,000 $ 200,000 Repayment - (100,000 ) (100,000 ) Balance as of September 30, 2024 $ - $ 100,000 $ 100,000 2022 Financing Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ 800,000 $ 1,675,000 $ 2,475,000 Issued 353,000 1,500,000 1,853,000 Conversion (700,000) (1,525,000 ) (2,225,000 ) Balance as of September 30, 2024 $ 453,000 $ 1,650,000 $ 2,103,000 On July 11, 2024, the board of directors (the “Board”) approved the closure of the 2022 Financing. Through September 30, 2024, the Company received 2022 Notes proceeds in the aggregate amount of $ 5,080,500 , of which $ 3,852,500 is from a related party investor (a Company officer/director). 2024 Financing Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ - $ - $ - Issued - 450,000 450,000 Balance as of September 30, 2024 $ - $ 450,000 $ 450,000 Balance $ - $ 450,000 $ 450,000 Through September 30, 2024, the Company received 2024 Notes proceeds in the aggregate amount of $ 450,000 2024 Repayment of 2021 Notes During the nine months ended September 30, 2024, the Company repaid $ 100,000 100,000 48,094 2024 Conversions of 2022 Notes into Preferred Stock During the three months ended September 30, 2024, principal and interest in the aggregate amount of $ 972,600 339,833 2.862 During the nine months ended September 30, 2024, principal and interest in the aggregate amount of $ 2,404,057 839,998 2.862 Interest expense on Convertible Notes Payable During the three and nine months ended September 30, 2024, the Company incurred $ 55,193 166,327 133,699 146,428

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of September 30, 2024 and December 31, 2023, the balance of the note payable was $ 110,544 277,815

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions During the three months ended September 30, 2024 and 2023, the Company incurred consulting fees of $ 0 63,600 63,600 190,800 250,000 258,000 Directors’ fees for Mr. Horowitz for the nine months ended September 30, 2024 and 2023 were $ 0 56,250 0 431,250 Mr. Horowitz waived the amount of $ 450,000 See Note 5 for details of other related party transactions. Directors’ fees incurred during the three months ended September 30, 2024 and 2023, were $ 77,500 96,250 251,250 288,750 0 2,330,589

Stockholders_ Deficit

Stockholders’ Deficit	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ Deficit	8. Stockholders’ Deficit Common Stock During the three and nine months ended September 30, 2024, holders of 75,776 757,760 Preferred Stock During the three months ended September 30, 2024, the Company issued 339,833 900,000 72,600 During the nine months ended September 30, 2024, the Company issued 839,998 2,225,000 179,057 During the three months ended September 30, 2024, the Company issued 744,878 2,131,839 2.862 On June 21, 2024, the Board approved the conversion of 11,416,242 Series D Preferred Shares held by Dominic Rodrigues, our President and Board vice chairman, into 1,141,626 shares of Series D-1 Preferred shares. See Note 12 for details on conversions of 2022 Notes into Series D-1 Preferred Stock subsequent to September 30, 2024. Number of Preferred Shares On June 24, 2024, the Company filed an amended Series D Certificate of Designation to decrease the authorized shares from 12,374,000 957,100 11,241,000 23,042,900 2024 Equity Compensation Plan At the shareholder meeting held on June 20, 2024, the proposal for the new 2024 Equity Compensation Plan was approved. The approval gives the Company the authority to grant Options and award Restricted Stock under the 2024 Equity Compensation Plan for up to 100,000,000 15 Options During the three and nine months ended September 30, 2024 and 2023, the Company did not have any issuances, grants, or exercises of options. The following table summarizes option activities during the nine months ended September 30, 2024: Schedule of Option Activity Weighted Average Weighted Average Remaining Aggregate Intrinsic Shares Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2024 3,225,000 $ 0.27 $ - Expired (150,000) 0.88 Outstanding and exercisable at September 30, 2024 3,075,000 $ 0.27 1.13 $ - The following table summarizes information about outstanding and exercisable options at September 30, 2024: Schedule of Stock Options Outstanding Options Outstanding Options Exercisable Outstanding Weighted Average Exercisable Number of Remaining Life Number of Exercise Price Options In Years Options $ 0.12 2,425,000 1.10 2,425,000 $ 0.29 100,000 1.10 100,000 $ 0.75 550,000 1.20 550,000 3,075,000 1.13 3,075,000 Warrants During the three and nine months ended September 30, 2024 and 2023, the Company did not have any issuances, grants, or exercises of warrants. The following table summarizes warrant activities during the nine months ended September 30, 2024: Schedule of Warrant Activity Number of Weighted Average Weighted Average Remaining Aggregate Intrinsic Warrants Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2024 412,500 $ 1.07 Expired (412,500 ) 1.07 Outstanding and exercisable at September 30, 2024 - $ - - $ - Annual Stockholder Meeting Proposals The Company held its annual meeting of stockholders on June 20, 2024. Stockholders authorized the Company’s board of directors (the “Board”) to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50, where the ratio would be determined by the Board at its discretion, and to make corresponding amendments to the Certificates of Designation to provide for the proportional adjustment of certain terms upon a reverse stock split, consistent with the Board’s recommendation. The Company’s stockholders also authorized the Board to amend the Company’s Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized shares of the Company’s common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent with the Board’s recommendation. The Board has not acted on these stockholder authorizations as of the filing date.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	9. Leases On June 18, 2022, the Company leased 2,700 three years 4,053 4,278 Total operating lease expense for the three months ended September 30, 2024 was $ 12,842 8,561 4,281 12,560 8,373 4,187 Total operating lease expense for the nine months ended September 30, 2024 was $ 38,686 25,791 12,895 38,739 25,826 12,913 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For the Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 35,662 $ 32,938 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 9 months 1 year 9 months Weighted Average Discount Rate Operating leases 5.0 % 5.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of September 30, 2024 were as follows: Future Minimum Payments Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2024 $ 12,835 2025 25,669 Total lease payments 38,504 Less: amount representing imputed interest (790 ) Present value of lease liability 37,714 Less: current portion (37,714 ) Lease liability, non-current portion $ -

Grants

Grants	9 Months Ended
	Sep. 30, 2024
Government Assistance [Abstract]
Grants	10. Grants On October 25, 2021, the Company received a grant award of $ 2,500,000 As of September 30, 2024 and December 31, 2023, $ 350,440 953,248 109,745 602,808 69,733 436,600

License Transactions

License Transactions	9 Months Ended
	Sep. 30, 2024
License Transactions
License Transactions	11. License Transactions In the third quarter of 2019, the Company entered into a dialog with Bascom Palmer Eye Institute (“BPEI”) regarding collaboration on BPEI’s ophthalmic photodynamic antimicrobial therapy (“PDAT”) using the Company’s pharmaceutical-grade RBS. On February 16, 2022, and later amended on May 11, 2022, the Company entered into an option agreement with the University of Miami (“UM”) for an exclusive worldwide license of intellectual property (“IP”) developed by the Ophthalmic Biophysics Center (“OBC”) of BPEI that included the use of OBC’s PDAT medical device in combination with formulations of the Company’s pharmaceutical-grade RBS for the treatment of bacterial, fungal, and viral infections of the eye. The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company paid $5,000 for the option that expires on May 31, 2023; agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP; and entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis. On March 21, 2024, the Company entered into an Exclusive License Agreement with the UM for the license and development of the University’s IP related to photodynamic antimicrobial therapy in ophthalmology. The License Agreement grants the Company exclusive, worldwide rights to research, develop, make, use, or sell Licensed Products and/or Licensed Processes based upon patent-related rights. As consideration for the rights granted in the License Agreement, the Company paid an upfront fee of $ 10,000 1,000 10,000 10% 30% The License Agreement provides that, within one year, the Company will create a corporation (“NewCo”) for the purpose of developing and commercializing Licensed Products and Licensed Processes, assign the License Agreement to NewCo, and enter into an equity agreement with respect to NewCo’s securities. Pursuant to the equity agreement, NewCo will be required to issue to the University 5% 2,000,000 The License Agreement sets forth certain diligence milestones that include forming NewCo, creating a Licensed Product suitable for submission to the Food and Drug Administration (“FDA”), generating Licensed Product data suitable for required submission to the FDA, submitting a drug-device combination application to the FDA, and receiving clearance, approval or other authorization from the FDA for the Licensed Product portion of the drug device combination. The License Agreement also provides for development milestone payments of $5,000 upon the first commercial sale of an approved Licensed Product and $50,000 upon net sales of Licensed Product of at least $500,000 The term of the License Agreement is the later of (i) the expiration or abandonment of all issued patents and patent applications related to patent rights under the License Agreement and/or no royalties are due, (ii) any regulatory exclusivity has expired, and (iii) 20 years from the first commercial sale of Licensed Product and/or Licensed Process. The License Agreement provides that the Company may terminate the License Agreement upon 90 days’ written notice to the University, and each party has the right to terminate the License Agreement if the other party commits a material breach of the terms of the License Agreement and such breach remains uncured for thirty days after receipt of written notice

Commitments, Contingencies and

Commitments, Contingencies and Litigation	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	12. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising from the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s condensed consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Convertible Notes Payable Subsequent to September 30, 2024, the Company entered into 2024 Notes with a related party investor (Executive Officer) in the aggregate principal amount of $ 50,000 Subsequent to September 30, 2024, the Company entered into 2024 Notes with non-related party investors in the aggregate principal amount of $ 400,000 Series D-1 Preferred Stock Subsequent to September 30, 2024, principal and interest in the aggregate amount of $ 54,033 18,880 2.862 NewCo Subsequent to September 30, 2024 and in connection with the License Agreement with UM, the Company entered into an agreement with non-related party investors for a seed round investment in NewCo, subject to negotiation, preparation, and execution of definitive agreements, after NewCo is created.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets.
Restricted Cash	Restricted Cash Restricted cash consists of a grant award received from the State of Tennessee. Restricted cash available as of September 30, 2024 is $ 426,732
Cash Concentrations	Cash Concentrations Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 364,189 776,799
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2024 2023 September 30, 2024 2023 Warrants - 437,500 Options 3,075,000 3,225,000 Convertible preferred stock 131,075,215 113,841,427 2021 unsecured convertible notes and accrued interest 517,451 817,766 2022 unsecured convertible notes and accrued interest 7,641,022 10,115,192 2024 unsecured convertible notes and accrued interest 1,578,423 - Total potentially dilutive shares 143,887,111 128,436,885
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 “ Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2024 2023 September 30, 2024 2023 Warrants - 437,500 Options 3,075,000 3,225,000 Convertible preferred stock 131,075,215 113,841,427 2021 unsecured convertible notes and accrued interest 517,451 817,766 2022 unsecured convertible notes and accrued interest 7,641,022 10,115,192 2024 unsecured convertible notes and accrued interest 1,578,423 - Total potentially dilutive shares 143,887,111 128,436,885

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Other Accrued Expenses	The following table summarizes the other accrued expenses at September 30, 2024 and December 31, 2023: Schedule of Other Accrued Expenses September 30, December 31, 2024 2023 Accrued payroll and taxes $ 1,280,049 $ 719,460 Accrued vacation 118,264 92,985 Accrued directors’ fees - 2,330,589 Accrued other expenses 160,026 97,402 Total other accrued expenses $ 1,558,339 $ 3,240,436

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ - $ 200,000 $ 200,000 Repayment - (100,000 ) (100,000 ) Balance as of September 30, 2024 $ - $ 100,000 $ 100,000 2022 Financing Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ 800,000 $ 1,675,000 $ 2,475,000 Issued 353,000 1,500,000 1,853,000 Conversion (700,000) (1,525,000 ) (2,225,000 ) Balance as of September 30, 2024 $ 453,000 $ 1,650,000 $ 2,103,000 Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2024 $ - $ - $ - Issued - 450,000 450,000 Balance as of September 30, 2024 $ - $ 450,000 $ 450,000 Balance $ - $ 450,000 $ 450,000

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Option Activity	The following table summarizes option activities during the nine months ended September 30, 2024: Schedule of Option Activity Weighted Average Weighted Average Remaining Aggregate Intrinsic Shares Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2024 3,225,000 $ 0.27 $ - Expired (150,000) 0.88 Outstanding and exercisable at September 30, 2024 3,075,000 $ 0.27 1.13 $ -
Schedule of Stock Options Outstanding	The following table summarizes information about outstanding and exercisable options at September 30, 2024: Schedule of Stock Options Outstanding Options Outstanding Options Exercisable Outstanding Weighted Average Exercisable Number of Remaining Life Number of Exercise Price Options In Years Options $ 0.12 2,425,000 1.10 2,425,000 $ 0.29 100,000 1.10 100,000 $ 0.75 550,000 1.20 550,000 3,075,000 1.13 3,075,000
Schedule of Warrant Activity	The following table summarizes warrant activities during the nine months ended September 30, 2024: Schedule of Warrant Activity Number of Weighted Average Weighted Average Remaining Aggregate Intrinsic Warrants Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2024 412,500 $ 1.07 Expired (412,500 ) 1.07 Outstanding and exercisable at September 30, 2024 - $ - - $ -

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For the Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 35,662 $ 32,938 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 9 months 1 year 9 months Weighted Average Discount Rate Operating leases 5.0 % 5.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future Minimum Payments Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2024 $ 12,835 2025 25,669 Total lease payments 38,504 Less: amount representing imputed interest (790 ) Present value of lease liability 37,714 Less: current portion (37,714 ) Lease liability, non-current portion $ -

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and restricted cash	$ 614,189						$ 614,189
Restricted cash	426,732			$ 1,042,957			426,732	$ 1,042,957
Working capital deficiency	5,464,760						5,464,760		$ 7,652,098
Net loss	$ (1,014,351)	$ (846,848)	$ (504,042)	$ (775,839)	$ (835,062)	$ (827,454)	(2,365,241)	(2,438,355)
Net cash used in operations							$ 2,372,083	$ 2,010,767

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	143,887,111	128,436,885
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		437,500
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,075,000	3,225,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	131,075,215	113,841,427
2021 Unsecured Convertible Notes and Accrued Interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	517,451	817,766
2022 Unsecured Convertible Notes and Accrued Interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	7,641,022	10,115,192
2024 Unsecured Convertible Notes and Accrued Interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	1,578,423

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Restricted cash	$ 426,732	$ 950,223
FDIC insurance limits	250,000
Cash and restricted cash balances in excess FDIC insured amount	$ 364,189	$ 776,799

Schedule of Other Accrued Expen

Schedule of Other Accrued Expenses (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued payroll and taxes	$ 1,280,049	$ 719,460
Accrued vacation	118,264	92,985
Accrued directors’ fees		2,330,589
Accrued other expenses	160,026	97,402
Total other accrued expenses	$ 1,558,339	$ 3,240,436

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
2021 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	$ 200,000
Issued	(100,000)
Balance	100,000
2021 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024
Issued
Balance
2021 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	200,000
Issued	(100,000)
Balance	100,000
2022 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	2,475,000
Balance	2,103,000
Issued	1,853,000
Conversion	(2,225,000)
2022 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	800,000
Balance	453,000
Issued	353,000
Conversion	(700,000)
2022 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	1,675,000
Balance	1,650,000
Issued	1,500,000
Conversion	(1,525,000)
2024 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024
Issued	450,000
Balance	450,000
2024 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024
Issued
Balance
2024 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024
Issued	450,000
Balance	$ 450,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Jul. 11, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Short-Term Debt [Line Items]
Interest expense on Convertible Notes Payable		$ (58,679)	$ (61,524)	$ (176,751)	$ (157,589)
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Accrued interest on convertible notes		$ 133,699		133,699		$ 146,428
2024 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Maximum financing amount	$ 10,000,000
Loan interest rate	8%
Proceeds from notes				450,000
2024 Convertible Notes Payable [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Convertible shares	10
2024 Convertible Notes Payable [Member] | Investor [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Share price per share	$ 2.8620
Conversion price per share	$ 2.8620
2022 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Proceeds from notes				5,080,500
2022 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Proceeds from notes				3,852,500
2024 Repayments of 2021 Notes [Member]
Short-Term Debt [Line Items]
Repaid Principal				100,000
Principal				100,000
Interest				$ 48,094
2024 Conversions of 2022 Notes [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Conversion price per share		$ 2.862		$ 2.862
Aggregate amount		$ 972,600		$ 2,404,057
Number of shares		339,833		839,998
2021 Notes [Member]
Short-Term Debt [Line Items]
Interest expense on Convertible Notes Payable		$ 55,193		$ 166,327
2022 Notes [Member]
Short-Term Debt [Line Items]
Interest expense on Convertible Notes Payable		55,193		166,327
2024 Notes [Member]
Short-Term Debt [Line Items]
Interest expense on Convertible Notes Payable		$ 55,193		$ 166,327

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Note payable	$ 110,544	$ 277,815

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended
	Jun. 27, 2024	Mar. 26, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Director fees			$ 77,500	$ 96,250	$ 251,250	$ 288,750
Accrued director fees			0		0		$ 2,330,589
Mr. Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Consulting fees			0	$ 63,600	63,600	190,800
Director fees					0	$ 56,250
Accrued director fees			$ 0		$ 0		$ 431,250
Mr Horowitz [Member]
Related Party Transaction [Line Items]
Consulting fees paid	$ 258,000	$ 250,000
Waived director fees	$ 450,000

Schedule of Option Activity (De

Schedule of Option Activity (Details)	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of options outstanding and exercisable, beginning balace | shares	3,225,000
Weighted average exercise price outstanding and exercisable, beginning balance | $ / shares	$ 0.27
Intrinsic Value, Outstanding | $
Stock options, expired | shares	(150,000)
Weighted average exercise price, expired | $ / shares	$ 0.88
Number of options outstanding and exercisable, ending balance | shares	3,075,000
Weighted average exercise price outstanding and exercisable, ending balance | $ / shares	$ 0.27
Weighted average remaining contractual life, exercisable	1 year 1 month 17 days
Intrinsic Value, Outstanding | $

Schedule of Stock Options Outst

Schedule of Stock Options Outstanding (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.27	$ 0.27
Outstanding	3,075,000	3,225,000
Weighted Average Remaining Contractual Life, Exercisable	1 year 1 month 17 days
Intrinsic Value, Outstanding
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding	3,075,000
Exercisable	3,075,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 1 month 17 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 1 month 17 days
Intrinsic Value, Outstanding	$ 3,075,000
Intrinsic Value, Exercisable	$ 3,075,000
Range One [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.12
Exercise Price, Exercisable	$ 0.12
Outstanding	2,425,000
Exercisable	2,425,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 1 month 6 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 1 month 6 days
Intrinsic Value, Outstanding	$ 2,425,000
Intrinsic Value, Exercisable	$ 2,425,000
Range Two [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.29
Exercise Price, Exercisable	$ 0.29
Outstanding	100,000
Exercisable	100,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 1 month 6 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 1 month 6 days
Intrinsic Value, Outstanding	$ 100,000
Intrinsic Value, Exercisable	$ 100,000
Range Three [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.75
Exercise Price, Exercisable	$ 0.75
Outstanding	550,000
Exercisable	550,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 2 months 12 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 2 months 12 days
Intrinsic Value, Outstanding	$ 550,000
Intrinsic Value, Exercisable	$ 550,000

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Equity [Abstract]
Warrants outstanding and exercisable, beginning balance | shares	412,500
Weighted average exercise price outstanding and exercisable, beginning balance | $ / shares	$ 1.07
Warrants, forfeited | shares	(412,500)
Weighted average exercise price, forfeited | $ / shares	$ 1.07
Warrants outstanding and exercisable, ending balance | shares
Weighted average exercise price outstanding and exercisable, ending balance | $ / shares
Weighted average remaining life in years
Aggregate intrinsic value | $

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)			3 Months Ended						9 Months Ended
	Jun. 21, 2024	Jun. 20, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Jun. 24, 2024	Jun. 23, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Accrued directors fees												$ 2,330,589
Preferred stock, shares authorized			25,000,000						25,000,000			25,000,000
2024 Equity Compensation Plan [Member]
Class of Stock [Line Items]
Stock issued during period share based compensation		100,000,000
Equity compensation plan for shares converted basis percentage		15
Common Stock [Member]
Class of Stock [Line Items]
Issuance of converted stock, shares			757,760
Series D-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			23,042,900						23,042,900	23,042,900	11,241,000	11,241,000
Series D-1 Convertible Preferred Stock [Member] | 2022 Notes [Member]
Class of Stock [Line Items]
Issuance of stock, shares			339,833						839,998
Conversion of principal			$ 900,000						$ 2,225,000
Conversion of accrued interest			$ 72,600						179,057
Series D-1 Convertible Preferred Stock [Member] | 2022 Notes [Member] | Director [Member]
Class of Stock [Line Items]
Issuance of stock, shares			744,878
Accrued directors fees			$ 2,131,839						$ 2,131,839
stock price			$ 2.862						$ 2.862
Series D-1 Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, shares			75,776						75,776
Issuance of converted stock, shares			757,760						757,760
Series D Preferred Stock [Member] | Board of Directors Chairman [Member]
Class of Stock [Line Items]
Issuance of converted stock, shares	11,416,242
Series D-1 Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Issuance of converted stock, shares			(75,776)
Stock Issued During Period, Shares, Conversion of Convertible Securities	1,141,626		339,833	273,691	226,474	122,725	188,757	18,872
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			957,100						957,100	957,100	12,374,000	12,374,000

Schedule of Right-of-use Assets

Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 35,662	$ 32,938
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Weighted Average Remaining Lease Term: Operating leases	9 months	1 year 9 months
Weighted Average Discount Rate: Operating leases	5%	5%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Non-cancellable Lease (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Leases
2024	$ 12,835
2025	25,669
Total lease payments	38,504
Less: amount representing imputed interest	(790)
Present value of lease liability	37,714
Less: current portion	(37,714)	$ (48,077)
Lease liability, non-current portion		$ 25,299

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 18, 2022 ft²
Research and Development Expense [Member]
Operating lease, expense	$ 8,561	$ 8,373	$ 25,791	$ 25,826
General and Administrative Expense [Member]
Operating lease, expense	4,281	4,187	12,895	12,913
Property Subject to Operating Lease [Member]
Operating lease, expense	$ 12,842	$ 12,560	38,686	$ 38,739
Knoxville, Tennessee [Member]
Area of land | ft²					2,700
Lessee, operating lease, term of contract					3 years
Knoxville, Tennessee [Member] | Minimum [Member]
Rent expenses per month			4,053
Knoxville, Tennessee [Member] | Maximum [Member]
Rent expenses per month			$ 4,278

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Oct. 25, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Government Assistance [Abstract]
Proceeds from grant	$ 2,500,000
Deferred revenue current		$ 350,440		$ 350,440		$ 953,248
Revenue		$ 109,745	$ 69,733	$ 602,808	$ 436,600

License Transactions (Details N

License Transactions (Details Narrative) - USD ($)		9 Months Ended
	Mar. 21, 2024	Sep. 30, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License transaction description		The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company paid $5,000 for the option that expires on May 31, 2023; agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP; and entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis.
Cash		$ 187,457	$ 76,576
Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of sublicense income	10%
Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of sublicense income	30%
Licensing Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Paid upfront fee	$ 10,000
Number of issued and outstanding shares, percentage	5%
Cash	$ 2,000,000
Development milestone payments, description	The License Agreement also provides for development milestone payments of $5,000 upon the first commercial sale of an approved Licensed Product and $50,000 upon net sales of Licensed Product of at least $500,000
First to Fourth Anniversaries License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty annual payments	$ 1,000
Fifth and There After Anniversaries License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty annual payments	$ 10,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Oct. 01, 2024 USD ($) $ / shares shares
2024 Notes [Member] | Related Party [Member]
Subsequent Event [Line Items]
Principal amount	$ 50,000
2024 Notes [Member] | Nonrelated Party [Member]
Subsequent Event [Line Items]
Principal amount	400,000
2022 Note [Member] | Series D-1 Convertible Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion of principal and interest	$ 54,033
Number of preferred stock converted | shares	18,880
Conversion price | $ / shares	$ 2.862